Christopher Graybill Joins ARCA as Vice President, Clinical Development
May 05, 2021 16:05 ET
| Source:
ARCA biopharma, Inc.
ARCA biopharma, Inc.
Westminster, Colorado, UNITED STATES
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development.
Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are delighted to welcome Christopher to ARCA as Vice President of Clinical Development. His over 14 years of experience in the biotechnology and medical device industries, supporting global clinical strategy, clinical trial planning and conduct, and other aspects of product development including in the cardiovascular space, will be a tremendous asset as we continue to advance the development of rNAPc2 and Gencaro.”